Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation-Reference-Cited by-同舟云学术

Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation

Published:2015-04-29 Issue:1 Volume:6 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Papaspyridonos Marianna,Matei Irina,Huang Yujie,do Rosario Andre Maria,Brazier-Mitouart Helene,Waite Janelle C.,Chan April S.,Kalter Julie,Ramos Ilyssa,Wu Qi,Williams Caitlin,Wolchok Jedd D.,Chapman Paul B.,Peinado Hector,Anandasabapathy Niroshana,Ocean Allyson J.,Kaplan Rosandra N.^ORCID,Greenfield Jeffrey P.,Bromberg Jacqueline,Skokos Dimitris,Lyden David

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms7840.pdf

Reference70 articles.

1. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).

2. Peinado, H., Lavotshkin, S. & Lyden, D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 21, 139–146 (2011).

3. Serafini, P., Borrello, I. & Bronte, V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16, 53–65 (2006).

4. Fricke, I. et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13, 4840–4848 (2007).

5. Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911–920 (2007).

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia;International Journal of Molecular Sciences;2024-08-30

2. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies;Experimental Hematology & Oncology;2024-08-06

3. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside;Experimental Hematology & Oncology;2024-08-01

4. Therapeutic targeting of TGF‐β in lung cancer;The FEBS Journal;2024-07-31

5. Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression;iScience;2024-03